Promomed values the trust of investors, works every day to strengthen the investment attractiveness of the company, and ensures maximum business transparency.
The pharmaceutical industry is at the peak of interest for investors. However, only a few companies in the sector are represented on the borrowings market.
Company plans for 2021-2025 provide for an increase in sales through the development and launch of new products and diversification of the current product portfolio.
Promomed Group revenue in 2021 amounted to 16.4 billion rubles (an increase of 70.9% compared to 2020).
Distribution of revenue by sales channels compared to 2020:
+ 133%, antiviral drugs
+ 25%, endocrinological drugs
+ 19%, antibacterial drugs
+ 10%, neurological drugs
+ 10%, drugs with various spectra of effect.
Sales of original medicines in 2021 increased 2.1 times compared to 2020.
Promomed Group's loan portfolio in 2021 grew by 22% compared to 2020, while short-term loans decreased by 28%.
The debt (loan) portfolio is diversified, including by two bond issues in 2020 and 2021 with a total volume of 2.5 billion rubles.
The total investment of Promomed Group in 2021 amounted to 3.3 billion rubles (an increase of 2.1 times compared to 2020.
Investments in the acquisition, creation, modernization and reconstruction of fixed assets increased 2.6 times compared to 2020. Investments in the acquisition and creation of intangible assets increased 1.9 times.
In 2022, the Expert RA rating agency assigned PROMOMED DM LLC the long-term credit rating ruA-.


Share and rating
among domestic manufacturers in 2021


Information disclosure

  • Messages
  • Accounting (financial) statements
  • Issue documents
  • Other documents